Alexandria Real Estate Equities ARE

$40.60 +0.69 (1.73%)

Valuation

Market cap
6,950,765,000
Revenue TTM
$3,026,560,000
Net income TTM
$-1,429,570,000
PE ratio
5.71
Forward PE
6.39
Profit margin
-47.23%
Debt to equity
0.67

Trading

Volume
2,588,600
Avg volume
2,242,120
Day's range
$39.71 – $41.50
Shares out
174,161,000
Stochastic %K
41%
Beta
1.16
Analysts
Hold
Price target
$50.00

Price

Company profile

Alexandria Real Estate Equities, Inc., an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovatio...

Show more

Alexandria Real Estate Equities, Inc., an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Megacampus™ ecosystems in AAA life science and advanced technology innovation cluster locations, including Greater Boston, San Diego, the San Francisco Bay Area, Seattle, Maryland, Research Triangle, and New York City. Alexandria Real Estate Equities, Inc. was established in 1994 and was incorporated in Maryland.

Industry
REIT - Office
Sector
Real Estate
Phone
626 578 0777
Website
https://www.are.com
Address
26 North Euclid Avenue, Pasadena, United States

Latest news

Stocktwits

Ayeeitsmee Oct 30, 3:48 AM
$ARE I think a big market change from ai tech to other plays is coming. Looks like this doubled bottomed for a reversal. Worst case it bottoms at $35 $36 support
0 replies
Daniel3303 Oct 29, 6:05 PM
$ARE Can someone explain me the 35% drop? What is wrong in the report that I don't see? For me the report was better than I expected...
0 replies
Daniel3303 Oct 29, 4:35 PM
$ARE something still wrong here, something still suppressing the price if you remove the macro effect from today
1 replies
Daniel3303 Oct 29, 3:46 PM
$ARE curious to see the 13F coming
0 replies
EliasTrader87 Oct 29, 2:42 PM
$ARE I'm taking a 4% profit 😉Hey bulls, don't get me wrong. But I like the bird in the hand...
0 replies
Richkid Oct 29, 12:30 PM
$ARE is this dividend safe?
2 replies
OnlyFibs Oct 29, 1:04 AM
🎯 $ARE | BULLISH SETUP Real Estate / Life Science REIT 🐂 ⭐ Setup Quality Grade: A- 📌 Grade Justification: • Profitability: Premier Life Science REIT Operator ($18B+ asset portfolio, high-quality investment-grade tenant base including Pfizer, Moderna & Eli Lilly). • Revenue Growth: Strong FFO (Funds From Operations) trajectory backed by high occupancy rates across AAA lab space clusters. • Technical Setup: A- Grade Cleanliness (8H long-term descending channel support retest holding $38.80–$39.58 spot on top of major volume shelf). • Wall St Target: +25%–40%+ Upside ($50.00–$56.00+ consensus price targets). 🏬 Profile: Leading owner and developer of collaborative life science and tech campuses in Boston, SF Bay Area, San Diego, and NYC. #are #optionsflow #hovdid
0 replies
Daniel3303 Oct 28, 9:08 PM
$ARE ’ 8-K wording is tricky: it says 2027 average occupancy falls vs year-end 2026. Why compare an average with a point in time? Because the trough is front-loaded. I think Dec ‘27 ends above Dec ‘26 (~87%). Losses: ~−6pts 1.4M SF of key expirations, mostly Jan–Mar (−4) Tenant wind-downs (−1) Non-renewals and redevelopment pivots (−1.5) Gains: +5 to +8pts 0.9M SF signed but not yet occupied (+2.5) Lease-up of vacant space (+1.5 to +3) Quick re-leases like BMS and Sequence (+0.5 to +1.5) Sales of vacant assets (+0.5 to +1) The H1 dip drags the average down; year-end shows the recovery. Watch the YE2027 occupancy range at the Dec 2 investor day.
0 replies